Charles Lyon, DPhil and Robert Sahr, PhD on FDA Regulation of Antibody Drug Conjugates

Intellectual Property Law360

 | July 20, 2015

 | Charles Lyon and Robert Sahr

View "Inside FDA Regulation of Antibody Drug Conjugates."

Charles Lyon and Robert Sahr wrote “Inside FDA Regulation of Antibody Drug Conjugates” in Intellectual Property Law360, where they discuss the FDA’s recent decision to regulate ADCs as biologics.  They explain that the antibody in an ADC provides the primary mode of action and thus should be regulated as such.  They also discuss the 12-year data package exclusivity period.  The article also appeared in Life Sciences Law360 and Public Policy Law360.


Thank you for reaching out to contact Choate. Before you send your message, we wanted to make sure you are aware of the following. Please do not send any confidential information in response to this link. Sending an e-mail to Choate does not give rise to an attorney-client relationship, and will not be deemed to disqualify Choate from undertaking any engagement for a current or future client.  Before any attorney-client engagement may be formed, Choate will need to check for possible conflicts of interest, you will need to consider whether you wish to retain Choate as counsel, and we will need to consider whether we wish to accept the potential engagement. In the meantime, Choate reserves the right to represent parties with interests adverse to you.